Early clinical trial supports tumor cell-based vaccine for mantle cell lymphoma

(Rockefeller University Press) A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient's own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment. The study, which will be published June 19 in the Journal of Experimental Medicine (JEM), reveals that the vaccines are a safe and effective way to induce the body's immune system to attack any tumor cells that could cause disease relapse.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news